Who are Pf-06804103's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TAK-788, PF-07220060 + PF-07104091 combination dose escalation, Ly4064809, High Dose PF-07328948, Treatment C, Pf-07284890.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-06804103.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Pf-06804103 — Competitive Intelligence Brief

Pf-06804103 (pf-06804103) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: not specified. Area: Oncology.

marketed not specified EGFR Exon 20 Insertion Mutations Oncology Live · refreshed every 30 min

Target snapshot

Pf-06804103 (pf-06804103) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pf-06804103 TARGET	pf-06804103	Pfizer	marketed	not specified	EGFR Exon 20 Insertion Mutations
TAK-788	TAK-788	Millennium Pharmaceuticals, Inc.	phase 3	EGFR tyrosine kinase inhibitor	EGFR exon 20 insertion mutations
PF-07220060 + PF-07104091 combination dose escalation	pf-07220060-pf-07104091-combination-dose-escalation	Pfizer	marketed	Not specified	Not specified
Ly4064809	ly4064809	Pfizer	marketed	Not specified	Not specified
High Dose PF-07328948	high-dose-pf-07328948	Pfizer	marketed	Not specified	Not specified
Treatment C	treatment-c	Pfizer	marketed	Not specified	Not specified
Pf-07284890	pf-07284890	Pfizer	marketed	Not specified	Not specified

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (not specified class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pf-06804103 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06804103. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab